201 results on '"Chirivella, Isabel"'
Search Results
2. SEOM clinical guideline on heritable TP53-related cancer syndrome (2022)
3. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
4. Two Germline Pathogenic Variants in Cancer Susceptibility Genes and Their Null Implication in Breast Cancer Pathogenesis: The Importance of Tumoral Homologous Recombination Deficiency Testing
5. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers
6. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study
7. Association of androgen receptor gene expression signature and ARV7with clinical outcome in metastatic hormone-sensitive prostate cancer.
8. Fertility and breast cancer: A literature review of counseling, preservation options and outcomes
9. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
10. Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
11. Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
12. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study
13. Molecular profiling and clinical relevance of low PTEN expression in patients with metastatic hormone-sensitive prostate cancer.
14. Prophylactic mastectomy and bilateral salpingo-oophorectomy in patients with breast cancer: a systematic review of postsurgical sexual function and menopausal hormone therapy symptom mitigation
15. Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)
16. Prophylactic mastectomy and bilateral salpingo-oophorectomy in patients with breast cancer: a systematic review of postsurgical sexual function and menopausal hormone therapy symptom mitigation.
17. Supplementary Data from Phase I Safety, Pharmacokinetics, and Inhibition of Src Activity Study of Saracatinib in Patients with Solid Tumors
18. Development and validation of a gene expression signature based on RB1, PTEN,and TP53 in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
19. Prevalence of germline MUTYH mutations among Lynch-like syndrome patients
20. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma
21. Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel
22. BRCA1 and BRCA2 mutations in males with familial breast and ovarian cancer syndrome. Results of a Spanish multicenter study
23. Estrogen receptor β and TMPRSS2-ERG expression association with clinical outcomes in metastatic hormone-sensitive prostate cancer.
24. Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes?
25. Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers
26. Hereditary Risk Assessment for BRCA Breast and/or Ovarian Cancer
27. Outcome Differences Between Patients With Node-Negative Breast Cancer Classified According to the St. Gallen Risk Categories
28. The deletion of exons 3–5 of BRCA1 is the first founder rearrangement identified in breast and/or ovarian cancer Spanish families
29. Evaluation of patients with metastatic renal cell carcinoma after failure of first-line treatment
30. Detection of a large rearrangement in PALB2 in Spanish breast cancer families with male breast cancer
31. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens
32. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers
33. Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients
34. Impact of mammography screening programme in the breast cancer population of the Region of Valencia (Spain)
35. Prevalence and Clinicopathological Characteristics of Moderate and High-Penetrance Genes in Non-BRCA1/2 Breast Cancer High-Risk Spanish Families
36. Association of androgen receptor signature and RB1, PTEN, TP53 gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.
37. Abstract PS7-71: Breast cancer fast-track programme to shorten time between initial symptoms, diagnosis and initiation of treatment. 10 years update
38. Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization
39. Hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC): Genotype and phenotype characteristics in a cohort of 197 patients.
40. PROREPAIR-A: Clinical and molecular characterization study of prostate cancer (PC) patients with and without previously known germline BRCA1/2 mutations.
41. HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
42. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
43. Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome in Spain: Clinical and Genetic Characterization
44. Preoperative chemoradiation followed by surgery and adjuvant chemotherapy for locally advanced rectal cancer: results of a quality control program in a multidisciplinary approach
45. Age as a prognostic factor for patients with non-metastatic breast cancer treated with adjuvant chemotherapy after initial surgery.
46. Supplementarytable_1 – Supplemental material for Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator
47. Additional file 2: of Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)
48. Additional file 4: of Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)
49. Additional file 3: of Implementation of massive sequencing in the genetic diagnosis of hereditary cancer syndromes: diagnostic performance in the Hereditary Cancer Programme of the Valencia Community (FamCan-NGS)
50. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.